Reuters logo
BRIEF-Galapagos and Gilead announce global partnership
December 17, 2015 / 6:14 AM / 2 years ago

BRIEF-Galapagos and Gilead announce global partnership

Dec 17 (Reuters) - Galapagos NV :

* Galapagos and Gilead announce global partnership to develop filgotinib for the treatment of rheumatoid arthritis and other inflammatory diseases

* Galapagos is eligible for payments up to $1.35 billion in milestones, with tiered royalties starting at 20 percent and a profit split in co-promotion territories

* Galapagos will receive an upfront payment of $725 million consisting of a license fee of $300 million and a $425 million equity investment in Galapagos

* Companies will start phase 3 trials in RA and Crohn’s in 2016 pending successful outcome of discussions with regulatory authorities Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below